Resultados globales: 1 registros encontrados en 0.01 segundos.
Artículos, Encontrados 1 registros
Artículos Encontrados 1 registros  
1.
12 p, 755.8 KB A randomised, open-label, parallel group phase 2 study of antisense oligonucleotide therapy in acromegaly / Trainer, Peter J. (Department of Endocrinology) ; Newell-Price, John D. C. (Royal Hallamshire Hospital) ; Ayuk, John (Medicine Endocrinology) ; Aylwin, Simon J. B. (King's College Hospital NHS Foundation Trust) ; Rees, Aled (Neuroscience and Mental Health Research Institute) ; Drake, William (Department of Endocrinology) ; Chanson, Philippe (Inserm 1185) ; Brue, Thierry (APHM) ; Webb, S. M 1952- (Institut d'Investigació Biomèdica Sant Pau) ; Fajardo, Carmen (Servicio de Endocrinología) ; Aller, Javier (Endocrinology Department) ; McCormack, Ann I (Garvan Institute of Medical Research and St Vincent's Hospital) ; Torpy, David J. (Royal Adelaide Hospital) ; Tachas, George (Antisense Therapeutics Limited) ; Atley, Lynne (Antisense Therapeutics Limited) ; Ryder, David (Manchester Academic Health Science Centre (MAHSC) Clinical Trials Unit) ; Bidlingmaier, Martin (Endocrine Laboratory) ; Universitat Autònoma de Barcelona
ATL1103 is a second-generation antisense oligomer targeting the human growth hormone (GH) receptor. This phase 2 randomised, open-label, parallel-group study assessed the potential of ATL1103 as a treatment for acromegaly. [...]
2018 - 10.1530/EJE-18-0138
European journal of endocrinology, Vol. 179 (may 2018) , p. 97-108  

¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.